Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 17/20 | 0.71 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12462412 | 1.00 | CHRM1 (0.71) | CHRM1CHRM5CHRM4KDM4EALDH1A1 | |
| SCHEMBL12462636 | 0.90 | CHRM1 (0.74) | CHRM1CHRM5CHRM4CHRM2USP2 | |
| SCHEMBL2148273 | 0.90 | CHRM1 (0.74) | CHRM1CHRM5CHRM4CHRM2USP2 | |
| SCHEMBL2147694 | 0.86 | CHRM1 (0.75) | CHRM1CHRM5CHRM4KDM4EALDH1A1 | |
| SCHEMBL12462641 | 0.86 | CHRM1 (0.75) | CHRM1CHRM5CHRM4KDM4EALDH1A1 | |
| SCHEMBL12462638 | 0.86 | CHRM1 (0.81) | CHRM1CHRM5CHRM4CHRM2USP2 | |
| SCHEMBL2147760 | 0.86 | CHRM1 (0.81) | CHRM1CHRM5CHRM4CHRM2USP2 | |
| SCHEMBL2287108 | 0.84 | CHRM1 (0.80) | CHRM1CHRM5CHRM4KDM4EALDH1A1 | |
| SCHEMBL2148339 | 0.83 | CHRM1 (1.00) | CHRM1CHRM5CHRM4KDM4EALDH1A1 | |
| SCHEMBL2148100 | 0.82 | CHRM1 (1.00) | CHRM1CHRM5CHRM4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697691-B2 | Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110172227-A1 | ALKYL 3-((2-AMIDOETHYL)AMINO)-8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXYLATE ANALOGS AS SELECTIVE M1 AGONISTS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172227-A1 | ALKYL 3-((2-AMIDOETHYL)AMINO)-8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXYLATE ANALOGS AS SELECTIVE M1 AGONISTS AND METHODS OF MAKING AND USING SAME | CHRM1, CHRM2, CHRM5 | CHRM1 1/4885CHRM5 3/4885CHRM4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.